Tablet Formulation Patent for HIV Capsid Inhibitor and NRTTI

The USPTO published patent application US20260090994A1 for pharmaceutical tablet formulations combining an HIV capsid inhibitor with a nucleoside reverse transcriptase translocation inhibitor (NRTTI) for treating HIV infections. The application covers the composition of matter and formulation details, with CPC classifications including A61K 9/2077, A61K 9/2018, A61K 9/2027, A61K 9/2031, A61K 9/2054, A61K 31/4439, and A61K 31/7076. Inventors include Benjamin Chal, Jay Poorna Reddy, Dhananjay Devidas Marathe, Marjorie Z. Imperial, James C. DiNunzio, Pavithra Sundararajan, Ryan Vargo, Diane M. Longo, Michelle Pham, and Diana Sperger.

This is a routine patent application publication with no compliance deadlines or regulatory obligations. Pharmaceutical companies, drug manufacturers, and researchers in the HIV therapeutic space should review the application's scope to assess potential freedom-to-operate considerations or partnership opportunities. No immediate action is required as patent applications do not impose enforceable obligations on third parties.